UOC
TXMD icon

UBS O'Connor’s TherapeuticsMD TXMD Stock Holding History

UBS O'Connor’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-7,820
Closed -$3.22M – 516
2016
Q1 		$2.5M Buy
7,820
+7,320
+1,464% +$2.5M 0.03% 303
2015
Q4 		$260K Sell
500
-1,007
-67% -$372K ﹤0.01% 401
2015
Q3 		$442K Sell
1,507
-10,133
-87% -$3.6M ﹤0.01% 467
2015
Q2 		$4.57M Buy
11,640
+1,966
+20% +$694K 0.04% 334
2015
Q1 		$2.93M Buy
9,674
+4,674
+93% +$1.14M 0.03% 348
2014
Q4 		$1.11M Buy
5,000
+500
+11% +$103K 0.02% 347
2014
Q3 		$1.04M Hold
4,500
– – 0.02% 340
2014
Q2 		$994K Sell
4,500
-500
-10% -$111K 0.01% 331
2014
Q1 		$1.58M Buy
+5,000
New +$1.59M 0.03% 299
2013
Q4 		– Sell
-2,000
Closed -$293K – 497
2013
Q3 		$293K Buy
+2,000
New +$242K 0.01% 346

Other funds holding TXMD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

UBS O'Connor's TXMD Position: Q2 2016 in Review

UBS O'Connor sold out of TherapeuticsMD (TXMD) in Q2 2016, closing a stake of 7,820 shares — an estimated $3.22M sold.

UBS O'Connor first reported a position in TXMD in Q3 2013 and held it in 10 quarters. The position peaked at $4.57M in Q2 2015. 123 funds tracked by Wall St. Rank hold TXMD as of Q2 2016.

  • UBS O'Connor reported no remaining TherapeuticsMD position as of Q2 2016 after selling out during the quarter.
  • UBS O'Connor sold 7,820 TherapeuticsMD shares in Q2 2016, an estimated $3.22M.
  • UBS O'Connor first reported a position in TherapeuticsMD in Q3 2013 and held it in 10 quarters.
  • UBS O'Connor's TherapeuticsMD position peaked at $4.57M in Q2 2015.
  • 123 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2016.

Based on UBS O'Connor's 13F filing for Q2 2016, filed 12 Aug 2016.